A Concise History of the Cancer and Leukemia Group B

Richard L. Schilsky,1 O. Ross McIntyre,2 James F. Holland,3 and Emil Frei III4

Abstract
A formal National Cancer Institute Clinical Trials Cooperative Group Program was conceived in 1955 when Dr. Sidney Farber, Mary Lasker, and others approached Congress with a proposal to increase support for studies of chemotherapy of cancer. In response, Congress awarded US $5 million to the National Cancer Institute to establish the Chemotherapy National Service Center. The founders of the Cancer and Leukemia Group B, James Holland and Emil (Tom) Frei, III, envisioned that successful chemotherapy for leukemia and other hematologic malignancies could be expeditiously realized through carefully designed clinical trials executed uniformly as a cooperative effort among several institutions. In 1956, the group was designated the Acute Leukemia Group B by the Chemotherapy National Service Center Clinical Studies Panel, and Frei was elected chairman. In the ensuing 50 years, the Cancer and Leukemia Group B has expanded to national and even international membership, and its research programs have expanded to include all of the common adult solid tumors and hematologic malignancies in a multidisciplinary effort to improve the outcomes for patients with cancer and to better understand the biology of malignant disease.

The Cancer and Leukemia Group B (CALGB) began to take shape in 1953 when James F. Holland arrived at the National Cancer Institute (NCI) upon the opening of the Clinical Center and initiated a clinical trial that combined two “targeted” therapies for treatment of acute leukemia (methotrexate and 6-mercaptopurine). The trial was based on studies by Lloyd Law of analogues of these agents in mice bearing L1210 leukemia that showed the combination to be curative. Holland moved to Roswell Park Memorial Institute (RPMI) in 1954, before the trial was completed, but Gordon Zubrod, the newly arrived chief of oncology at NCI, agreed to continue the study in Bethesda, thus initiating the first multicenter study of acute leukemia. The founders of the CALGB, James F. Holland and Emil (Tom) Frei, III, who had been recruited by Zubrod, envisioned that successful chemotherapy for leukemia and other hematologic malignancies could be expeditiously realized through carefully designed clinical trials executed uniformly as a cooperative effort among several institutions.

A formal NCI Clinical Trials Cooperative Group Program was conceived in 1955 when the National Cancer Institute (NCI) approved the opening of the Clinical Center at the National Cancer Institute (NCI). Holland was one of several oncologists who approached Congress with a proposal to increase support for studies of chemotherapy of cancer. In response, Congress awarded US $5 million to NCI to establish the Chemotherapy National Service Center Clinical Studies Panel, and Frei was elected chairman. In the ensuing 50 years, the Cancer and Leukemia Group B has expanded to national and even international membership, and its research programs have expanded to include all of the common adult solid tumors and hematologic malignancies in a multidisciplinary effort to improve the outcomes for patients with cancer and to better understand the biology of malignant disease.
A formal disease committee structure, including committees on Breast Cancer, Respiratory Cancer, GI Cancer, and Other Tumors, was put in place at that time.

In 1979, the pediatric division of CALGB was disapproved in peer review. The bulk of that membership joined with the former pediatric members of the Southwest Oncology Group to form the Pediatric Oncology Group. Many of the fundamental principles of chemotherapy and the groundbreaking studies that showed the curability of childhood acute leukemia were accomplished by ALGB. In a coherent and inter-related series of studies spanning 25 years, the Group first showed the importance of combination chemotherapy for ALL, the value of maintenance chemotherapy after remission induction, the role of vincristine and prednisone for remission induction, the importance of methotrexate dose scheduling, the use of intrathecal methotrexate, and the importance of timing in the scheduling of asparaginase. These observations and principles provided the foundation for combination chemotherapy studies of solid tumors and the framework for conducting multicenter clinical trials. Indeed, the founders of CALGB and the other cooperative groups invented many of the standard clinical trial procedures used today. Eligibility criteria, toxicity grading, response criteria, uniform data collection tools, quality assurance measures, and the fundamental principles of statistical analysis of clinical trials can all trace their origins to early cooperative group studies.

Immunotherapy studies, focused on the use of the methanol extractable residue of Bacillus Calmette-Guerin, were initiated by CALGB in 1975. This agent was studied in detail across multiple disease areas, and the correlative studies that accompanied the clinical trials led to the formation of an Immunology Committee with expertise in immunodiagnosis and monitoring of immune function. Under the leadership of Clara Bloomfield, this committee evolved over time to become the Immunology and Cytogenetics Committee, the forerunner of the Correlative Science for Leukemia and Lymphoma Committee and the current Leukemia Correlative Science Committee.

A Psychiatry Committee was formed under the leadership of Jimmie C. Holland in 1976 to bring quantitative assessment to important aspects of cancer therapy, such as quality of life, symptom management, and patient compliance. Pathology was also established as a modality committee in 1976, and the Group adopted a new Constitution and By Laws in 1978 that affirmed the primacy of multidisciplinary research in CALGB and the key role of modality committees in the scientific leadership of the Group.

In 1980, Tom Frei was again elected Group Chair and put in place the scientific and administrative structure that supports CALGB to this day. Oliver Glidewell was succeeded by Jim Anderson as Group Statistician; Brad Patterson was appointed Chief of Staff in the Central Office; and Karen Antman, now Dean of the Boston University School of Medicine, served as Assistant to the Chairman, a role analogous to that of Executive Officer today.

Since then, the CALGB research program has become even more diverse and multidisciplinary. In 1990, Ross McIntyre was elected Chairman, and in the next 5 years, he organized the Solid Tumor Correlative Science, Surgery, and Prostate Cancer Committees. He also conducted a national search for a new Group Statistician and Statistical Center that led to the
appointment of Stephen George as Group Statistician and the relocation of the CALGB Statistical Center to Duke University. Since 1995, under Schilsky’s leadership, the CALGB has continued to diversify, now involving experts in molecular biology, pharmacogenomics, geriatrics, imaging, economics, health outcomes, and cancer prevention in CALGB activities.

The pioneering efforts of the Group’s founders, the substantial financial contributions of the NCI, foundations, and the pharmaceutical industry coupled with the contributions of other cooperative groups and research centers have allowed progress in cancer treatment that could scarcely have been imagined 50 years ago. The CALGB is proud of its record of achievement. In the articles that follow, current CALGB leaders summarize the accomplishments of CALGB in specific disease and modality areas over the last 50 years and describe how the work of the Group has introduced new therapies, changed treatment paradigms, improved quality of life and survival, and provided important insights into cancer biology that are the foundation for the next 50 years of progress in the fight against cancer.

Acknowledgments

We have been privileged to lead an extraordinary group of creative and dedicated physicians, laboratory scientists, statisticians, nurses, clinical research associates, administrative staff, and other oncology specialists over the past 50 years. The accomplishments of CALGB belong to them and to our colleagues in the other cooperative groups and at the NCI. None of the accomplishments of the cooperative group program would have been achieved without the courageous participation of tens of thousands of patients with cancer and their family members. We are inspired by them and devoted to using all the tools at our disposal to extend their survival and improve the quality of their lives.

Baptist Cancer Institute CCOP, Memphis, TN—Lee S. Schwartzberg, MD, supported by CA31946; CALGB Statistical Center, Durham, NC—Stephen George, Ph.D., supported by CA33601; CALGB CCOP Research Base grant CA37474; CALGB Surgery Committee grant CA59594; Cancer Centers of the Carolinas, Greenville, SC—Jeffrey K. Giguere, M.D., supported by CA29165; Cedars-Sinai Medical Center, Los Angeles, CA—Alan T. Leventhal, Christiana Care Health Services, Inc., CCOP, Wilmington, DE—Stephen Grubbis, MD., supported by CA45418; Community Hospital—Sacramento CCOP, Sacramento, CA—Jeffrey Kirshner, MD, supported by CA45389; Dana Farber Partners, Boston, MA—George P Cano, MD, supported by CA32299; Dartmouth Medical School—Norris Cotton Cancer Center, Lebanon, NH—Marc S. Einhorn, MD, supported by CA04326; Duke University Medical Center, Durham, NC—Jeffrey Crawford, MD, supported by CA47545; Emory University, Atlanta, GA—Harvey B. Neill, MD, supported by CA47559; Fox Chase Cancer Center, Philadelphia, PA—Jeffrey S. Crawford, MD, supported by CA101140; Fred Hutchinson Cancer Center, Seattle, WA—David A. Mullins, MD, supported by CA45407; Garvan Institute, Sydney, Australia—James A. Turbayne, MD, supported by CA34457; Georgia Cancer Center for Excellence, Augusta, GA—Gary G. Doan, MD, supported by CA74811; Georgia Institute of Technology, Atlanta, GA—Tanya B. Dill, MD, supported by CA09186; Harvard Medical School, Boston, MA—Christopher J. Pich, MD, supported by CA29165; Huntsman Cancer Institute, Salt Lake City, UT—Jill A. Hackett, MD, supported by CA39157; Houston University of Health and Science Center, Houston, TX—Jenny Newberry, MD, supported by CA47554; Indiana University, Indianapolis, IN—Stephen J. Freudenberg, MD, supported by CA32295; Institute of Cancer Research, London, UK—Mark E. Gurney, MD, supported by CA29165; Iowa State University, Ames, IA—Richard L. Schilsky, MD, supported by CA31946; Korea University, Seoul, Republic of Korea—Myung-Ha Lee, MD, supported by CA32295; Lane Cancer Institute, Portland, OR—Michael J. Kalton, MD, supported by CA32295; Leiden University Medical Center, Leiden, The Netherlands—Johan De Vries, MD, supported by CA47554; Memorial Sloan Kettering Cancer Center, New York, NY—Charles A. Hyman, MD, supported by CA101140; Memorial Sloan Kettering Cancer Center, New York, NY—Robert A. Miller, MD, supported by CA47545; Michigan State University, East Lansing, MI—Michael S. Kastan, MD, supported by CA34457; Memorial Sloan Kettering Cancer Center, New York, NY—William P. Reichert, MD, supported by CA29165; Memorial Sloan Kettering Cancer Center, New York, NY—Joseph P. Riley, MD, supported by CA47554; Memorial Sloan Kettering Cancer Center, New York, NY—Walter P. Schuchter, MD, supported by CA34457; Memorial Sloan Kettering Cancer Center, New York, NY—Richard S. Wacker, MD, supported by CA34457; Memorial Sloan Kettering Cancer Center, New York, NY—Teresa Silvano, MD, supported by CA34457; Massachusetts General Hospital, Boston, MA—Jeffrey S. Kolligs, MD, supported by CA32295; Massachusetts General Hospital, Boston, MA—Michael L. Grossbard, MD, supported by CA12449; McGill University, Montreal, QC—Gerald Batist, MD; Medical University of South Carolina, Charleston, SC—Mark Green, MD, supported by CA03927; Missouri Baptist Medical Center CCOP, St. Louis, MO—Alan P. Lyons, MD CA114558; Memorial Sloan-Kettering Cancer Center, New York, NY, Clifton Hudis, MD, supported by CA77651; Mount Sinai Medical Center, Miami, FL—Rogerio Lilenbaum, MD, supported by CA45564; Mount Sinai School of Medicine, New York, NY—Lewis R. Silverman, MD, supported by CA04457; North Shore - Long Island Jewish Medical Center, Manhasset, NY—Daniel R. Budman, MD, supported by CA35278; Northern Indiana Cancer Research Consortium CCOP, South Bend, IN—Rafat Ansari, MD, supported by CA86726; Rhode Island Hospital, Providence, RI—William Silkov, MD, supported by CA8025; Roswell Park Cancer Institute, Buffalo, NY—Elis Levine, MD, supported by CA02599; Southeast Cancer Control Consortium Inc. CCOP, Goldsboro, NC—James N. Atkins, MD, supported by CA45808; Southern Nevada Cancer Research Foundation CCOP, Las Vegas, NV—John Elerton, MD, supported by CA54241; State University of New York Upstate Medical University, Syracuse, NY—Stephen L. Graziano, MD, supported by CA21060; Southwestern Medical Center—Dallas, TX—Peter Ward, MD, supported by CA46418; Stanford University, Stanford, CA—Arielle Lieberman, MD, supported by CA45407; Stanford University, Stanford, CA—Bruce R. Alberts, Ph.D., supported by CA29165; State University of New York Upstate Medical University—Syracuse, NY—Jeffrey K. Giguere, MD, supported by CA45389; The Ohio State University Medical Center, Columbus, OH—Clara D. Bloomfield, MD, supported by CA77658; University of Alabama Birmingham, Birmingham, AL—Robert Diasio, MD, supported by CA47545; University of California at San Diego, San Diego, CA—Joanne Mortimer, MD, supported by CA11793; University of California at San Francisco, San Francisco, CA—Alan P. Venook, MD, supported by CA60138; University of Chicago, Chicago, IL—Gini Fleming, MD, supported by CA41287; University of Illinois MBCCOP, Chicago, IL—Lawrence E. Feldman, MD, supported by CA74811; University of Iowa, Iowa City, IA—Gerald Clamon, MD, supported by CA47642; University of Maryland Greenbaum Cancer Center, Baltimore, MD—Martin Edelman, MD, supported by CA31983; University of Massachusetts Medical School, Worcester, MA—William V. Walsh, MD, supported by CA37735; University of Minnesota, Minneapolis, MN—Bruce A. Peterson, MD, supported by CA16450; University of Missouri/Ellis Fischel Cancer Center, Columbia, MO—Michael C. Perry, MD, supported by CA12046; University of Nebraska Medical Center, Omaha, NE—Anne Kessinger, MD, supported by CA77298; University of North Carolina at Chapel Hill, Chapel Hill, NC—Thomas C. Shea, MD, supported by CA47559; University of Tennessee Memphis, Memphis, TN—Harvey B. N陕ll, MD, supported by CA47558; University of Texas Southwestern Medical Center, Dallas, TX—Debashis Tripathy, MD—Vermont Cancer Center, Burlington, VT—Hyman B. Muss, MD, supported by CA77406; Virginia Commonwealth University Massey Cancer Center CCOP, Richmond, VA—John D. Roberts, MD, supported by CA52784; Wake Forest University School of Medicine, Winston-Salem, NC—David D. Hurd, MD, supported by CA03927; Walter Reed Army Medical Center, Washington, DC—Thomas Reid, MD, supported by CA26806; Washington University School of Medicine, St. Louis, MO—Nancy Bartlett, MD, supported by CA77440; Weill Medical College of Cornell University, New York, NY—Scott Wadler, MD, supported by CA07968; Western Pennsylvania Cancer Institute, Pittsburgh, PA—Richard K. Shadduck, MD; The Leukemia Committee has also been supported in part by National Cancer Institute grant CA101140; The Leukemia Correlative Science Committee has also been supported in part by National Cancer Institute grants CA101140; CA16058, and The Coleman Leukemia Research Foundation. The Pharmacology and Experimental Therapeutics Committee has also been supported in part by National Cancer Institute grant CA44691.

Reference


www.aacrjournals.org 3555s Clin Cancer Res 2006;12(11 Suppl) June 1, 2006

Downloaded from clincancerres.aacrjournals.org on July 1, 2021. © 2006 American Association for Cancer Research.
Clinical Cancer Research

A Concise History of the Cancer and Leukemia Group B


Updated version

Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/12/11/3553s

Cited articles

This article cites 1 articles, 1 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/12/11/3553s.full#ref-list-1

Citing articles

This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/12/11/3553s.full#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/12/11/3553s.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.